David Oscier

TL;DR: The International MDS Risk Analysis Workshop combined cytogenetic, morphological, and clinical data from seven large previously reported risk-based studies that had generated prognostic systems as discussed by the authors.

TL;DR: In this article, the finding of homozygous EZH2 mutations in 9 of 12 individuals with 7q acquired uniparental disomy was described, and the mutations resulted in premature chain termination or direct abrogation of histone methyltransferase activity.

TL;DR: It is concluded that V617F is widespread in MPDs and detection of this acquired mutation is likely to have a major impact on the way patients with MPD are diagnosed, as well as serving as an obvious target for signal transduction therapy.

TL;DR: ZAP-70 expression and IgVH mutation status were comparable in their ability to predict time to treatment requirement following diagnosis, and reverse transcriptase-polymerase chain reaction and immunohistochemical assays for ZAP- 70 expression can be applied clinically and would yield important prognostic information for patients with CLL.

TL;DR: A meta-analysis of these data and those of two published phase III trials showed a consistent benefit for the fludarabine plus cyclophosphamide regimen in terms of progression-free survival.